Paradigm of combination biologics: Analytical challenges related to pharmacokinetic assays and interpretation of pharmacokinetic and immunogenicity results

Bioanalysis

Volumn 3, Issue 5, 2011, Pages 487-498

  Stevenson, Lauren ^a   Zinnack, Kimberly ^a   Donley, Jean ^a   Beebe, Lisa ^a   Amaravadi, Lakshmi ^a  

^a BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1; MONOCLONAL ANTIBODY 2; UNCLASSIFIED DRUG;

ACCURACY; ANTIBODY DETECTION; ARTICLE; CROSS REACTION; DRUG POTENTIATION; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOGENICITY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PROTEIN TARGETING; SENSITIVITY AND SPECIFICITY; TOXICITY TESTING;

ANIMALS; ANTIBODIES, MONOCLONAL; DATA INTERPRETATION, STATISTICAL; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNITY; MACACA FASCICULARIS;

EID: 79953121633     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.10.214     Document Type: Article

References (16)

1. Bankhurst AD. Etanercept and methotrexate combination therapy. Clin. Exp. Rheumatol. 17(6), S69-S72 (1999). (Pubitemid 29503361)
2. Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH. Comparison of the efficacy of the tumour necrosis factor a blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 62(2), ii13-ii16 (2003).
3. Klareskog L, van der Heijde D, de Jager JP et al. TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial. Lancet 363(9410), 675-681 (2004). (Pubitemid 38296553)
4. Lipsky PE, van der Heijde DM, St Clair EW et al. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. infliximab and methotrexate in the treatment of rheumatoid arthritis. anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N. Engl. J. Med. 343(22), 1594-1602 (2000).
5. Lovell DJ, Ruperto N, Goodman S et al. Pediatric rheumatology collaborative study group; pediatric rheumatology international trials organisation. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N. Engl. J. Med. 359(8), 810-820 (2008).
6. Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised Phase III trial. ATTRACT study group. Lancet 354(9194), 1932-1939 (1999).
7. Weisman MH, Moreland LW, Furst DE et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-a monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study. Clin. Ther. 25(6), 1700-1721 (2003). (Pubitemid 36801943)
8. DeSilva B, Smith W, Weiner R et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 20(11), 1885-1900 (2003). (Pubitemid 37449466)
9. Kelley M, DeSilva B. Key elements of bioanalytical method validation for macro-molecules. AAPS J. 9(2), E156-E163 (2007). (Pubitemid 46812967)
10. Smolec J, DeSilva B, Smith W et al. Bioanalytical method validation for macromolecules in support of pharmacokinetic studies. Pharm. Res. 22(9), 1425-1431 (2005). (Pubitemid 41215881)
11. Lee J, Ma H. Specificity and selectivity evaluations of ligand-binding assay of protein therapeutics against concomitant drugs and related endogenous proteins. AAPS J. 9(2), E164-E170 (2007). Describes several case study examples and highlights the importance of evaluating specificity in bioanalytical assays in the context of concomitant therapeutics.
12. Huang SM, Strong JM, Zhang L et al. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J. Clin. Pharmacol. 48(6), 662-670 (2008). (Pubitemid 351713150)
13. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin. Pharmacokinet. 49(8), 493-507 (2010).
14. Zhang L, Reynolds KS, Zhao P, Huang SM. Drug interactions evaluation: An integrated part of risk assessment of therapeutics. Toxicol. Appl. Pharmacol. 243(2), 134-145 (2010).
15. Lee JI, Zhang L, Men AY, Kenna LA, Huang SM. CYP-mediated therapeutic protein-drug interactions: Clinical findings, proposed mechanisms and regulatory implications. Clin. Pharmacokinet. 49(5), 295-310 (2010).
16. Ponce R, Abad L, Amaravadi L et al. Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studies. Regul. Toxicol. Pharmacol. 54(2), 164-182 (2009). Describes the immunological basis of antidrug antibodies formation and outlines different approaches for the interpretation of nonclinical data to support progression to clinical evaluation.